{"prompt": "['Trelagliptin-4002', 'Page 57 of 66', 'Version 1.0', 'November 2, 2016', 'Total number of daily tablets, including medication for treatment of comorbidities', '(<2 tablets or 2 tablets)', 'Number of doses of the study drug or comparative drug (once weekly, once daily or', 'twice daily)', 'Changes in the scores per question in the DTR-QOL Questionnaire at each assessment time', 'point.', 'Changes in the scores for per question in the DTSQ at each assessment time point.', '1)', 'Summary statistics for measurements and the changes from the baseline (Week 0) will be', 'calculated per treatment group.', 'Other endpoints>', 'Summarizations below will be performed in the \"full analysis set\" (FAS).', 'Laboratory tests', 'Treatment compliance of each study subject will be calculated and summary statistics of', 'compliance per treatment group will be presented.', 'Treatment compliance', 'Treatment compliance of each study subject will be calculated and summary statistics of', 'compliance per treatment group will be presented.', 'The Basic Information on Study Subject (Your Basic Profile)', 'Frequency of answers to each question at each visit will be analyzed per treatment group.', '13.1.4 Safety analysis', 'Frequency tables will be prepared for the incidences of adverse events, hypoglycemia, and', 'hospitalization for type 2 diabetes (number and duration of hospitalization) after the first', 'administration of the study drug or comparative drug administration in the \"safety population\" in', 'each treatment group.', '13.2', 'Criteria for interim analysis and premature discontinuation', 'No interim analysis is planned.', '13.3', 'Determination of the number of planned study subject', 'In this clinical study, to discuss changes in the total score for all questions in the DTR-QOL', 'Questionnaire from the baseline (Week 0) to the end of the treatment period, as the primary endpoint,', 'mean changes in the daily DPP-4 inhibitor and trelagliptin groups were assumed as 14.4% and', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 58 of 66', 'Version 1.0', 'November 2, 2016', '19.0%, respectively. The mean change in the daily DPP-4 inhibitor group was assumed by reference', 'to the data on SGLT2 inhibitor, from the previous research 4). and that in trelagliptin group was', 'assumed by reference to the data from the validation trial of the DTR-QOL Questionnaire 6) The', 'common SD was assumed as 12.1 % considering the former assumption. When 5% of significance', 'level (two-sided) is based for the analysis of the primary endpoint, 110 subjects per group would be', 'needed to ensure 80% power in comparisons between the trelagliptin group and daily DPP-4', 'inhibitor group. As this is a study on treatment for type 2 diabetes with DPP-4 inhibitors currently', 'used in the medical setting, the number of randomized subjects was established as 120 subjects per', 'group, for a total of 240 subjects, assuming a type 2 diabetes treatment discontinuation rate of 8%*.', '*Based on the results for Topic 2 of the \"Strategic Studies on the Prevention of Diabetes\" (JDOIT-2),', 'the annual discontinuation rate for the \"usual care group\" without intervention is approximately 8%', '2)', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 59 of 66', 'Version 1.0', 'November 2, 2016', '14.0 QUALITY CONTROL AND QUALITY ASSURANCE', '14.1', 'Monitoring of the study site', 'The sponsor or the designee shall perform periodic monitoring of the study site during the study to', 'confirm that the study is conducted in accordance with all specifications in the study protocol. In the', 'monitoring, the data recorded on the CRF will be checked by comparing them with those in the', 'source documents. Source documents are the original documents, data and records. The principal', 'investigator and the chief executive of the study site shall ensure that the sponsor or the designee and', 'the Ethical Review Board, etc., have access to the source documents.', 'The sponsor or the designee shall access the records, including the list of study subject ID codes,', 'medical records of the study subjects, and signed and dated original consent forms to confirm that', 'the study is appropriately conducted in compliance with the study protocol. Also, confirm the', 'consistency between CRF and the related source documents. The principal investigator, investigator,', 'and other personnel involved in the study shall spare sufficient time to facilitate monitoring', 'procedures during visits to the study site.', 'Detailed procedures for monitoring shall be described separately in the written procedures.', '14.2', 'Deviation from the Ethical Guidelines for Medical and Health Research', 'Involving Human Subjects and the study protocol', 'The principal investigator or investigator shall record all deviations from Ethical Guidelines for', 'Medical and Health Research Involving Human Subjects, and study protocol.', 'If any deviation is found, the principal investigator shall promptly notify the chief executive of the', 'study site for the clinical study and the sponsor. As necessary, the principal investigator will discuss', 'protocol revisions with the sponsor to reach agreement. For protocol revisions, draft revisions should', 'be submitted as early as possible to the chief executive of the study site for approval of the', 'committee such as the Ethical Review Board.', '14.3', 'Quality assurance audits and regulatory agency inspections', 'The sponsor or the designee shall perform audit at the study site as necessary. In such a case, the', 'auditor designated by the sponsor shall contact the study site in advance to determine the date of', 'audit. The auditor may ask to visit the facilities where laboratory specimens are collected and any', 'other facilities used during the clinical study. In addition, this study may be inspected by regulatory', 'agencies, including those of foreign governments (e.g., the Food and Drug Administration [FDA],', 'the United Kingdom Medicines and Healthcare products Regulatory Agency [MHRA]). If the study', 'site is contacted for an inspection by a regulatory body, the sponsor should be notified promptly. The', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}